Dear All, During their recent turn to hold the EU presidency (1 Jan to 30 Jun 2023), the Swedes have steadily pushed AMR as one of their top priorities. As part of this, Sweden used their most recent presidency to release a motion to adopt a Council Recommendation on fighting AMR. Here are the parallel links that
Dear All, In case you missed it, the 4th AMR Conference sponsored by BEAM, CARB-X, Novo REPAIR, Wellcome Trust, the UK, and many others (link) is in full swing through Friday 28 Aug. The webinar technology is working well, the content is excellent, I’m seeing several hundred participants in the sessions, and chat rooms are
Note: For those of you with an interest in developing bacterial vaccines, the results of Pfizer’s failed STRIVE S. aureus vaccine have now appeared in print along with an excellent editorial commentary. Deep sigh on this one — please see the updated prior newsletter for the links and the full story. Dear All, Today we
Addendum: This is the third in a 3-newsletters series on this topic. Go here and here for the prior newsletters. Finally, the results of the STRIVE trial have been published as Hassanzadeh et al. in Clinical Infectious Diseases (2023;77:312-20, https://doi.org/10.1093/cid/ciad218). There is also an accompanying editorial (Proctor RA, https://doi.org/10.1093/cid/ciad217) that provides an excellent discussion of the
Dear All, Long note alert! There are two deep and deeply connected topics to share today. Refresh your coffee and settle in… Today’s first topic: Adding to the recent reviews of the clinical stage pipeline for both traditional products (link to the Sep 2019 Pew Charitable Trusts summary), and non-traditional products (link to an Aug 2019 newsletter summarizing
Dear All, I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here. Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion
Dear All, The high-value webinars below have just crossed my radar. First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the
Dear All, First up for today, WHO’s GLASS (Global Antimicrobial Resistance and Use Surveillance System) have released an update to their ongoing work that provides global data through 2020. Here the links you need: The GLASS dashboard The GLASS report An insightful LinkedIn post on the way(s) that the data can now be used: you
Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act. Here’s what you need: Blog: “The World Needs New Antibiotics.
Dear All, Based on a 2020 RFP, we’ve known that WHO was building a fungal priority pathogen list (PPL). Well, now the list has been released. Here’s what you need to understand the new PPL: Webpage where you can get the report My PowerPoint .pptx that summarizes all the PPLs to date My webpage that provides
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust